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Abstract
RasGAP is a multifunctional protein that controls Ras activity and that is found in chromosomal passenger complexes. It also
negatively or positively regulates apoptosis depending on the extent of its cleavage by caspase-3. RasGAP has been
reported to bind to G3BP1 (RasGAP SH3-domain-binding protein 1), a protein regulating mRNA stability and stress granule
formation. The region of RasGAP (amino acids 317–326) thought to bind to G3BP1 corresponds exactly to the sequence
within fragment N2, a caspase-3-generated fragment of RasGAP, that mediates sensitization of tumor cells to genotoxins.
While assessing the contribution of G3BP1 in the anti-cancer function of a cell-permeable peptide containing the 317–326
sequence of RasGAP (TAT-RasGAP317–326), we found that, in conditions where G3BP1 and RasGAP bind to known partners,
no interaction between G3BP1 and RasGAP could be detected. TAT-RasGAP317–326 did not modulate binding of G3BP1 to
USP10, stress granule formation or c-myc mRNA levels. Finally, TAT-RasGAP317–326 was able to sensitize G3BP1 knock-out
cells to cisplatin-induced apoptosis. Collectively these results indicate that G3BP1 and its putative RasGAP binding region
have no functional influence on each other. Importantly, our data provide arguments against G3BP1 being a genuine
RasGAP-binding partner. Hence, G3BP1-mediated signaling may not involve RasGAP.
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Introduction
There is an ongoing need to improve current anti-tumor
regimens to reduce the rate of death due to cancer. In this
context, we discovered earlier that the caspase-3-generated
RasGAP N-terminal fragment (RasGAP158–455), called N2, was
able to selectively sensitize cancer cells, but not healthy cells, to
genotoxin-induced apoptosis [1]. RasGAP amino acids 317 to
326 within fragment N2 were found to carry this sensitizing
activity [2]. A cell-permeable peptide containing this sequence
(the so-called TAT-RasGAP317–326 peptide) was then generated
[2]. This peptide potently enhances the efficacy of genotoxins to
selectively kill cancer cells, both in in vivo [3] and in vitro [2]
settings. TAT-RasGAP317–326 does not induce apoptosis by itself
making it a pure sensitizer compound [2–4]. The understanding
of its mode of action is of particular relevance in the context
of the mechanisms allowing cancer cells to resist apoptosis. It is
known that TAT-RasGAP317–326 favors genotoxin-induced
mitochondrial outer membrane depolarization (MOMP) and
caspase-3 activation [5]. The RasGAP-derived peptide requires a
functional p53/PUMA axis to induce its genotoxin-sensitization
effect [5]. However, this might only reflect the fact that
genotoxins require the p53/PUMA axis to optimally kill
cancer cells [6,7]. At present, the direct molecular target(s) of
TAT-RasGAP317–326 are unknown and the cellular events
underlying its sensitizing properties are only minimally under-
stood.
GAP SH3 Binding Protein 1 (G3BP1) is one of the molecules
described to interact with RasGAP. This was first reported by
Parker et al. in 1996 [8] who identified and cloned a molecule able
to bind to the SH3 domain of RasGAP. Incidentally, this
interaction only took place in serum-stimulated cells. The binding
between RasGAP and G3BP1 could be prevented by a peptide
corresponding to sequence 317–326 found within the RasGAP
SH3 domain. These data were corroborated by two other reports
showing that G3BP1 binds to RasGAP in proliferating cells [9]
and that the G3BP1 domain responsible for these binding was the
nuclear transfer factor 2 (NTF2)-like domain, located at its N-
terminus [10]. This domain was also described to mediate the
binding of the yeast orthologue of G3BP1 (Bre5) to the Ubp3
deubiquitinating enzyme [11]. G3BP1 seems not to be a substrate
of USP10, the Ubp3 mammalian orthologue, but it appears to
inhibit the capacity of USP10 to cleave ubiquitin chains [12]. The
C-terminal portion of G3BP1 contains two canonical RNA
recognition motifs (RRMs) indicating that G3BP1 has RNA-
binding capacities. Indeed G3BP1 was reported to co-immuno-
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precipitate with mRNAs and to bind to and cleave the 39
untranslated region (39UTR) of the c-myc mRNA in vitro [9].
Interestingly, the endoribonuclease activity of G3BP1 is governed
by its phosphorylation status. In proliferating cells, when G3BP1 is
hypo-phosphorylated, it loses its ability to cleave mRNA whereas
in quiescent cells, when it is hyper-phosphorylated, it does cleave
mRNAs [9]. This observation suggested a possible role of G3BP1
in coupling extra-cellular stimuli to mRNA stability. This
hypothesis is supported by the finding that G3BP1 is implicated
in stress granule (SG) assembly [13]. SGs correspond to
cytoplasmic loci where mRNAs are stored during stress conditions
and where the decision to degrade or convert them into
translationally active mRNA protein complexes (mRNPs) is taken
once the stress has subsided [14–16]. Formation of stress granules
in cells may inhibit apoptosis [17].
The observation that G3BP1 binds to RasGAP on the very
same sequence that mediates the tumor sensitizing activity of
fragment N2 and the fact that G3BP1 is over-expressed in some
cancer cells made G3BP1 a good candidate for the TAT-
RasGAP317–326 peptide ability to lower the resistance specifically
in cancer cells. We therefore investigated whether the known
functions attributed to G3BP1 could be modulated by TAT-
RasGAP317–326 and whether G3BP1 was required for the peptide
to sensitize tumor cells to genotoxin-induced apoptosis.
Materials and Methods
Cell lines and transfection
U2OS (LGC Promochem; ATCC nu HTB-96), HCT116 [18],
HEK293T [19], HeLa cells (LGC Promochem; ATCC nu CCL-
2), and CCL39 cells (LGC Promochem; ATCC nu CCL-39), as
well as wild-type and G3BP1 knock-out mouse embryonic
fibroblasts (MEFs) [20] were maintained in DMEM (Invitrogen
reference nu61965) containing 10% fetal calf serum (GIBCO/
BRL reference nu10270-106, lot nu41Q6001K) at 37uC and 5%
CO2. HEK293T and U2OS cells were transfected using the
calcium/phosphate precipitation procedure [2,21].
Buffers
The composition of phosphate buffered saline (PBS) is
116 mM NaCl, 10.4 mM Na2HPO4, 3.2 mM KH2PO4
(pH 7.4). The Stag lysis buffer is made of 50 mM Hepes
pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA pH 8.0,
10% glycerol, 1% Triton X-100, and is supplemented with one
tablet of EDTA-free inhibitor (Roche) per 50 ml. The
composition of sample buffer 2X is 25 mM 2-amino-2-(hydro-
xymethyl)-1,3-propanediol (Tris) HCl pH 6.5, 10% glycerol, 6%
SDS, 0.02% of bromophenol blue and 100 mM freshly added
dithiothreitol (DTT). The 1% Triton X-100 lysis buffer is made
of 20 mM Hepes pH 7.4, 150 mM NaCl, 1% Triton X-100,
1 mM MgCl2, 1 mM EGTA and 1 mM NaVO4 supplemented
with one tablet of EDTA-free inhibitor [Roche] per 50 ml. The
RIPA-like lysis buffer is made of 50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1% NP-40, 0.25% deoxycholic acid, 1 mM
EGTA and 1 mM NaVO4 supplemented with one tablet of
EDTA-free inhibitor (Roche) per 50 ml. The composition of
sample buffer 5X is 250 mM Tris-HCl pH 7, 10% SDS, 30%
glycerol, 5% b-mercaptoethanol. Tris buffer saline (TBS) is
made of 20 mM Tris base, 130 mM NaCl, pH 7.6.
Antibodies
The monoclonal antibody specific for the hemagglutinin (HA)
tag was purchased as ascites from BabCo (reference nuMMS-
101R). This antibody was adsorbed on HeLa cell lysates to
decrease non-specific binding as described previously [22]. Mouse
anti-human G3BP1 was from BD Transduction Laboratories
(reference nu611127). The rabbit polyclonal anti human TIA-1
antibody was from Santa Cruz (reference nusc-28237) The anti S-
Protein HRP-conjugated antibody was from Novagen (reference
nu69047). The anti-GST antibody was from Upstate (reference
nu06-332). The polyclonal rabbit anti-c-Myc antibody was from
Cell Signaling (reference nu9402). The polyclonal rabbit anti-
RasGAP antibody directed at the Src homology (SH) domains of
RasGAP was from Enzo Life Sciences (reference nuALX-210-860-
R100). The monoclonal mouse anti-SV40 large T antigen was
from BD Pharmingen (reference nu554149). The rabbit anti-
USP10 antibody was provided by Dr. Olivier Staub (University of
Lausanne, Switzerland). The monoclonal mouse anti-V5 antibody
was from Invitrogen (reference nu46-0705). Secondary antibodies
were donkey anti-mouse fluorescein-conjugated antibody and
donkey anti-rabbit Cy3-conjugated antibody (Jackson ImmunoR-
esearch, reference nu715-095-1507 and 711-165-152, respective-
ly).
Plasmids
The extension .dn3 indicates that the backbone plasmid is
pcDNA3 (#1) (Invitrogen). S?tag corresponds to the first 15 amino
acids of the S-peptide of RNase A (amino acids 1–15 of RNAse A).
The S?tag is able to bind with high affinity to the S protein (amino
acid 21–124 of RNAse A) [23,24]. TRIP-PGK-IRESNEO-
WHV (#350) is a lentiviral vector bearing the neomycine
resistance. The pEGFP-C1 plasmid (#6) encodes the green
fluorescent protein and is from Clonetech. The hG3BP1.dn3
plasmid (#322) encodes human G3BP1 [8]. HA-rRhoGAP.prc
(#196) encodes the HA-tagged form of rat p190RhoGAP. The
6xHis-Stag-mUSP10.dn3 plasmid (#646) encoding the poly-
histidine- and S-tagged form of mouse USP10 was described
earlier [25]. HA-hRasGAP.dn3 (#118), previously called HA-
GAP.dn3 [22], encodes the HA-tagged form of human RasGAP.
HA-hRasGAP[158–455].dn3 (#145), previously called HA-
N2.dn3 [22], encodes the HA-tagged form of fragment N2. HA-
hRasGAP[1–455](D157A).dn3 (#352), previously called N-
D157A.dn3 [22], encodes the HA-tagged caspase-3-resistant form
of fragment N. V5-hRasGAP[3–455](D157A).dn3 (#585)
encodes a V5-tagged version of the caspase-3-resistant form of
fragment N that lacks its first two methionine residues (to prevent
potential internal translation events). It was constructed by PCR
amplifying HA-hRasGAP[1–455](D157A).dn3 with oligonucleo-
tide #559 [AA (feeder sequences) GGTACC (KpnI site)
GCCACC (Kozak sequence) ATG GGA AAA CCA ATA CCA
AAT CCA CTA CTA GGC CTA GAC AGT ACA (V5 tag)
GCG GCC GAG GCC GGC AGTG (sequences complementary
to RasGAP from third amino acid on; nucleotides 124–133 of the
human RasGAP mRNA; entry M23379)] and oligonucleotide
#560 [GCA ACG AAG TGG GCA GTT TG (sequences lying
within the human RasGAP mRNA downstream of the SacII site;
nucleotides 489–469 of human RasGAP mRNA; entry M23379)].
The resulting 427 bp PCR fragment was cut with KpnI and SacII
and subcloned in HA-hRasGAP[1–455](D157A).dn3 opened with
the same enzymes. V5-hRasGAP[3-1931].dn3 (#686) encodes
a V5-tagged version of human RasGAP that lacks its first two
methionine residues (to prevent potential internal translation
events). It was made by subcloning the SpeI/SacII fragment of
V5-hRasGAP[3–455](D157A).dn3 into HA-hRasGAP.dn3
opened with the same enzymes. HA-hG3BP1.dn3 (#541)
encodes an HA-tagged version of human G3BP1. It was produced
by PCR amplifying the hG3BP1.dn3 plasmid with oligonucleotide
#501 [AAAA (feeder sequences), GGATCC (BamHI site),
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GGATCC (Kozak sequence), ATG GGC TAC CCG TAC GAC
GTG CCG GAC TAC GCT TCT (HA tag), ATG GTG ATG
GAG AAG CCT AG (nucleotides 172–191 of the human G3BP1
mRNA; NCBI entry NM_005754) and oligonucleotide #502
[TTTTT (feeder sequences), GTCGAC (SalI site) TTC ACT
GCC GTG GCG CAA GCC CCC TTC (nucleotides 1573–1547
of the human G3BP1 mRNA; NCBI entry NM_005754). The
resulting 1465 bp fragment was blunted with T4 DNA polymerase
(Promega reference nuM421A), digested with BamHI and
subcloned into pcDNA3 opened with BamHI and EcoRV.
Stag-GFP.dn3 (#647) encodes an S-tagged form of the green
fluorescent protein (GFP). It was generated by PCR amplifying
plasmid pEGFP-C1 with oligonucleotide #686 [AAAAAA
(feeder), GGATCC (BamHI site), GCCACC (Kozak sequence),
ATG AAA GAA ACC GCT GCT GCT AAA TTC GAA CGC
CAG CAC ATG GAC AGC (S?tag), ATG GTG AGC AAG
GGC GAG GA (first 20 coding nucleotides of GFP)] and with
oligonucleotide#687 [AAA (feeder), CCG TCG ACT GCA GAA
TTC GAA GC (nucleotides of pEGFP-C1 surrounding the EcoRI
site; underlined)]. The amplified PCR fragment was then digested
with BamHI and EcoRI and subcloned into pcDNA3 opened with
the same enzymes. Stag-hRasGAP[158–455].dn3 (#754)
encodes the S-tagged form of fragment N2 and was constructed
by PCR amplifying plasmid HA-hRasGAP[158–455].dn3 with
oligonucleotide #796 [TAAGCAG (feeder sequence), AAGCTT
(HindIII), CTCGAG (XhoI), CCACC (Kozak sequence; the last
nucleotide of the XhoI recognition site provides the G at the 26
Kozak position), ATG GCG (start codon and alanine codon),
AAA GAA ACC GCT GCT GCT AAA TTC GAA CGC CAG
CAC ATG GAC AGC (S?tag) TCT CTG GAT GGA CCA GAA
TA (first 21 base pairs of fragment N2) and oligonucleotide #679
[GCA TTT AGG TGA CAC TAT AG (nucleotides 1018–999 of
pcDNA3)]. The resulting 1027-base pairs PCR fragment was then
digested with HindIII and subcloned in HA-hRasGAP[158–
455].dn3 opened with the same enzyme. SV40LargeTantigen.
pBABE-puro (#731) encodes the SV40 large T antigen
(Addgene; plasmid 13970). SV40LargeTantigen.lti-neo
(#738) similarly encodes the large T antigen but in a lentiviral
expression vector. It was constructed by subcloning the BamHI
2187 base pairs fragment of SV40LargeTantigen.pBABE-puro
into TRIP-PGK-IRESNEO-WHV opened with the same enzyme.
Non-target.pLKO-puro (#584) corresponds to a pLKO.1-puro
lentiviral expression vector containing a shRNA insert that does
not target human and mouse genes (Sigma Aldrich, reference
nuSHC002). shRNA-hG3BP1.pLKO-puro (#641) encodes a
shRNA targeting a sequence within the 39UTR of the human
G3BP1 mRNA (nucleotides 1976–1997 of entry NM_005754). It
was purchased from Sigma Aldrich. 6xHis-hRasGAP[279–
343].pET28 (#544) encodes a histidine-tagged form of the
SH3 domain of RasGAP. It was constructed as follows. HA-
hRasGAP(no 39UTR).dn3 (#424) [1] was amplified by PCR using
oligonucleotide #505 [AT (feeder) CATATG (NdeI site) AGA
AGG CGT GTA CGA GCT AT (human RasGAP; nucleotides
959-978 of NCBI entry M23379)] and oligonucleotide #506 [AT
(feeder) GCGGCCGC (NotI site) CTA (stop codon) CCG GCC
CAC CTC CTC TAC TA (human RasGAP; nucleotides 1143–
1122 of NCBI entry M23379)]. The amplified fragment was cut
with the NdeI and NotI restriction enzymes and the resulting 192
base pair fragment was subcloned into vector pET-28a(+) (#543)
opened with the same enzymes. A PCR-generated A to G silent
mutation was found at position 1129 (numbering based on NCBI
entry M23379) in 6xHis-hRasGAP[279–343].dn3. His-TAT-
GFP (#130) encodes a fusion protein made of a stretch of 6
histidine residues, the TAT sequence, and GFP.
SNTAG pull down
Two millions U2OS cells were seeded in a six-well plate and the
next day transfected using the calcium/phosphate precipitation
procedure. After an additional 24-hour period, cells were lysed in
Stag lysis buffer and 1 mg of the lysates were incubated with 1 ml
of biotinylated S-protein (Novagen; reference nu69218) for 3 hours
at 4uC. Thirty ml of streptavidin beads (GE Healthcare Bio-
Sciences; reference nu17-5113-01) were then added to the samples
and the incubation resumed for an additional 1-hour period. Pull
down complexes were then washed 3 times with PBS, 1% NP40
and solubilized in 30 ml of sample buffer 2X.
Immunoprecipitation
One million cells (either CCL39 or U2OS) were seeded in 10-
cm plates and 24 hours later the cells were lysed in 1% Triton X-
100 lysis buffer. Alternatively, one million HEK 293T cells were
seeded in 10-cm plates and 24 hours later they were transfected
using the calcium/phosphate precipitation procedure. After an
additional 24-hour period they were lysed in RIPA-like lysis buffer.
Protein content was measured by Bradford. Seven hundreds mg of
total protein were immunoprecipitated with 1 mg of the anti-
RasGAP antibody overnight at 4uC with rotation at 9 rpm.
Twenty ml of G protein sepharose beads (GE Healthcare;
reference nu17-0618-01) were then added for an additional 2 hour
period. Immunocomplexes were then washed three times with
washing buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1%
NP-40) and solubilized in 30 ml of sample buffer 2X. Samples were
heated 10 minutes at 95uC before loading.
Quantitative PCR
RNA was isolated with the ‘‘High Pure RNA isolation kit’’
(Roche; reference nu 11828665001) according to the manufactur-
er’s instruction. The RNA was then reverse-transcribed with the
‘‘Transcriptor high fidelity cDNA kit’’ (Roche; reference nu05 091
284 001) as per the manufacturer’s instruction. Quantitative PCR
assays were carried out on a real-time PCR detection system (iQ5;
Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad; reference nu
170–8862) using primers at a 500 nM concentration. The
sequences of the c-myc specific primers were GGA CGA CGA
GAC CTT CAT CAA (oligonucleotide#728, nucleotide 926–946
of c-myc mRNA, NCBI entry: NM_002467.3) and CCA GCT
TCT CTG AGA CGA GCT T (oligonucleotide #729, nucleotide
996–1017 of c-myc mRNA, NCBI entry: NM_002467.3). The 18S
ribosomal RNA was used for normalization. The primers used to
amplify this RNA were GCA ATT ATT CCC CAT GAA CG
(oligonucleotide #774, nucleotide 1617–1636, NCBI entry:
NR_003278.1) and GGC CTC ACT AAA CCA TCC AA
(oligonucleotide #775, nucleotide 1720–1739, NCBI entry:
NR_003278.1).
Western blotting
Two hundred thousand cells were seeded in six-well plates and
24 hours later they were subjected to the treatments indicated in
the figures after which they were lysed in sample buffer 5X.
Proteins were quantitated using the Bradford method. Equal
amounts of proteins were subjected to SDS-PAGE and then
transferred onto a nitrocellulose membrane (Biorad; reference
nu162 0115). The membranes were blocked with TBS containing
0.1% Tween-20 and 5% non-fat milk and incubated overnight at
4uC with the indicated primary antibodies used at 1:1000 dilution.
Blots were then washed with TBS-Tween 0.1%, incubated with
the appropriate secondary antibody (1:5000 dilution) 1 hour at
room temperature and subsequently visualized with the Odyssey
G3BP1 and the 317–326 Sequence of RasGAP
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e29024
infrared imaging system (LICOR Biosciences, Bad Homburg,
Germany).
Lentivirus
Recombinant lentiviruses were produced as described [26].
Briefly, HEK293T cells were co-transfected using the calcium
phosphate DNA precipitation method [21] with 50 mg of the
lentiviral vector (TRIP-PGKATGm-MCS-WHV) containing the
cDNA of interest (i.e. G3BP1 shRNA), 2.5 mg of the envelope
protein–coding plasmid (pMD.G), and 7.5 mg of the packaging
construct (pCMVDR8.91). Two days after transfection, the virus-
containing medium was harvested. Infection of the cells was
performed as follows. Hexadimethrine bromide (Polybrene;
Sigma; reference nu52495) was added to cells cultured in six-well
plates at a final concentration of 5 mg/ml followed by the addition
of the lentivirus. The plates were then centrifuged 45 minutes at
800 g and placed 24 hours at 37uC in a 5% CO2 humidified
atmosphere. The medium was then replaced with fresh medium,
and the cells were further cultured for an additional 48 hour
period before being used in specific experiments.
Immunocytochemistry
Two hundred thousand cells were seeded in six-well plates
containing glass coverslips and 24 hours later they were transfect-
ed with the calcium/phosphate precipitation procedure. One day
post-transfection, the cells were fixed as follows (all steps were
performed at room temperature). The cells on coverslips were
washed with 4 ml of PBS, fixed with 3 ml PBS, 3% formaldehyde,
3% sucrose for 10 minutes, washed thrice with PBS, permeabi-
lized with 2 ml of PBS, 0.2% Triton X-100 for 10 min, washed
thrice with PBS, and incubated 30 minutes with 3 ml of filtered
serum-containing culture medium. After three additional PBS
washes, the coverslips were incubated for 1 hour with the primary
antibody diluted in DMEM, 10% newborn calf serum. The
coverslips were washed 3 times over 30 minutes in PBS and then
incubated 1 hour with a 1/100 dilution of labeled secondary
antibodies in DMEM, 10% newborn calf serum. The coverslips
were washed 3 more times in PBS and labeled when indicated
with 10 mg/ml Hoechst 33342 (Molecular Probe) before being
mounted (Vectashield mounting medium, Vector laboratories
Inc). Confocal images were captured with a Leica SP5 AOBS
confocal microscope.
Determination of G3BP1 nuclear content
Confocal images were converted to tif format and opened with
the Adobe Photoshop Elements 5.0 software. Pictures of Hoechst-
stained cells were used to create masks of the nuclei that were then
overlaid on the pictures of G3BP1-stained cells in order to delimitate
the nuclear area. The nuclear G3BP1 signal image was then opened
using the ImageJ software (1.34n version) and the nuclear signal was
quantitated. Similarly, the total G3BP1 staining was quantitated for
each picture with the ImageJ software (in this case the cell contours
were manually drawn). The nuclear G3BP1 signal was calculated as
the percentage of the total G3BP1 cell staining.
Peptides
TAT and TAT-RasGAP317–326 are retro-inverso peptides (i.e.
synthesized with D-amino acids in the opposite direction
compared to the natural sequence). The TAT moiety corresponds
to amino acids 48–57 of the HIV TAT protein
(RRRQRRKKRG) and the RasGAP317–326 moiety corresponds
to amino acids 317–326 of the human RasGAP protein
(DTRLNTVWMW). These two moieties are separated by two
glycine linker residues in the TAT-RasGAP317–326 peptide. The
peptides were synthesized at the Department of Biochemistry,
University of Lausanne, Switzerland, using FMOC technology,
purified by HPLC and tested by mass spectrometry.
Protein production and purification
Plasmids coding for recombinant proteins were expressed in
BL21 E. coli. Bacteria were grown overnight in lysogeny broth (LB)
medium (casein enzymic hydrolysate 10 g/l, yeast extract 5 g/l,
NaCl 170 mM, pH 7.5). The induction of the recombinant proteins
was performed by the addition of 0.1 mM isopropyl-beta-thio-
galactoside (IPTG) to the culture medium when it reached on
optical density at 600 nm of 0.6. After 4 hours of induction, the cells
were harvested and resuspended in 5 ml Buffer A [HEPES 50 mM,
magnesium acetate 200 mM, NaCl 500 mM, Triton X-100 0.1%,
lysozyme 2 mg/ml, 0.5% b-mercaptoethanol and 10 mg/ml
DNaseI, supplemented with one tablet of EDTA-free inhibitor
(Roche) per 50 ml]. In order to fully lyse the cells, the suspension
was sonicated (Heischer DmBH sonicator, 0.9 cycles per second,
80% amplitude) 4 times 30 seconds on ice and then centrifuged
20 minutes at 9’000 g at 4uC. A sample of the lysate was kept to
verify the induction of the protein. GST-tagged proteins were then
purified. The glutathione-sepharose beads (Amersham Pharmacia
Biotech; reference nu17-0756-01) were washed 3 times with PBS
and then incubated with the lysate at 4uC with rotation (Labinco
rotary mixer, 12 rpm). The beads were washed thrice with PBS. To
elute the recombinant protein, the beads were incubated with
500 ml of glutathione elution buffer (50 mM Tris pH 8, 10 mM
reduced glutathione [Sigma reference nuG-4251]) for 15 minutes at
4uC with rotation. The beads were then pulled down at 4’000 g and
the supernatant was collected. Histidine-N2 recombinant proteins
were produced as described above, except that nickel beads were
used (Ni-NTA agarose, Qiagen; reference nu1000632) instead of
glutathione-Sepharose beads. The elution step was then performed
with buffer A (see above) supplemented with 25 mM imidazole
(Sigma reference nuI2399).
Statistics
All the statistical analyses were done with Microsoft Excel (XP
edition) using the unpaired Student’s t test. Significance is
indicated by an asterisk when P,0.05/n, where P is the
probability derived from the t test analysis and n is the number
of comparisons done (Bonferroni correction).
In silico protein docking assays
The G3BP1 NTF2 domain structure (PDB entry #2Q90) was
first refined using Maestro v90211 in order to complete and refine
the loops. Molecular dynamics simulations were conducted using
the AMBER 11.0 force field from the NAMD 2.7 package. Using
AmberTools 11.0, the resulting system was solvated in a
rectangular box extending 12 A˚ around the molecule using TIP3P
water molecules. Sodium and chloride ions were added to
neutralize the system. Five thousand steps of energy minimization
were applied on the entire system. Following minimization, the
system was equilibrated with 5’000 steps of water-only molecular
dynamics at 150uK, the system was heated from 0 to 300uK for
100 picoseconds. After heating, a 5 nanosecond production
simulation was conducted with a 1 picosecond time step at a
pressure of 1 bar and a temperature of 300uK. The RasGAP SH3
domain (PDB entry #2JO5) was optimized using the same
method. The docking was performed using Hex 5.1 standard
parameters. The 150 best poses out of 10’000 were collected and
analyzed. The resulting complexes were ranked according to their
free interactions energy. The same docking method was applied to
G3BP1 and the 317–326 Sequence of RasGAP
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the SH3 domain of RasGAP and sequence 190–233 of UBP3, the
USP10 yeast orthologue (PDB entry #2QIY).
Results
No evidence for a RasGAP-G3BP1 interaction
Previous data indicated that G3BP1 binds to a discrete sequence
of RasGAP within its SH3 domain that corresponds to amino
acids 317–326 of the protein [8]. As fragment N2 bears this SH3
domain, we postulated that it should allow fragment N2 to bind to
G3BP1. However, Figure 1 shows that in HEK 293T cells
fragment N2 failed to pull down G3BP1 in conditions where
USP10, a deubiquitinating enzyme known to interact with G3BP1
[12], did. It could be argued that the 317–326 sequence is not
accessible on fragment N2 while it would be exposed on the
parental full-length protein. We therefore assessed if an interaction
between RasGAP and G3BP1 could be demonstrated. Figure 2
indicates that RasGAP could not co-immunoprecipitate with
G3BP1, while it did with p190 RhoGAP, a known RasGAP
binding partner [27,28]. G3BP1 binding to RasGAP has been
reported in the CCL39 (Chinese hamsters lung fibroblast) cell line
[9]. Conceivably, this interaction could be cell-type specific.
Therefore, we immunoprecipitated RasGAP from both CCL39
cells and U2OS cells. Figure 3 shows that endogenous RasGAP
protein interacted with p190 RhoGAP in both cell lines. In these
conditions, no interaction could be detected between RasGAP and
G3BP1.
TAT-RasGAP317–326 does not affect the binding of G3BP1
to USP10
It might be argued that the G3BP1-RasGAP interaction is
transient and difficult to detect by the techniques we have used
here. This interaction might nevertheless occur and one could
hypothesize that TAT-RasGAP317–326 sensitizes tumor cells by
modulating G3BP1 functions by either inhibiting the binding of
RasGAP to G3BP1 or by mimicking the binding of RasGAP to
G3BP1. One of the reported functions of G3BP1 is to bind to and
inhibit USP10 [12]. We therefore assessed if TAT-RasGAP317–326
could prevent the binding of G3BP1 to this protein. Figure 4
shows that the interaction of G3BP1 to USP10 was unaffected by
TAT-RasGAP317–326, indicating that the peptide does not affect
the inhibitory function of G3BP1 on USP10.
TAT-RasGAP317–326 does not impair stress granule
formation
In response to environmental stress (i.e. heat and oxidative
conditions) eukaryotic cells stop the translation of constitutive
Figure 1. G3BP1 does not bind to RasGAP-derived fragment N2. Lysates (1 mg) from HEK293T cells that had been transfected with the
indicated plasmids were subjected to SNTAG pull-down. Pulled-down complexes were then analyzed by Western blotting using an HA-specific
antibody. In parallel, 50 mg of total cell lysates were subjected to Western blot analysis using antibodies recognizing HA or the SNTAG.
doi:10.1371/journal.pone.0029024.g001
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expressed mRNAs that are then routed to phase-dense cytoplas-
mic granules called stress granules (SGs). Many RNA-binding
proteins participate in SG assembly including G3BP1, which
together with TIA-1, is a SG marker [16]. An attractive hypothesis
was that TAT-RasGAP317–326 mediates its sensitization effect by
inhibiting the capacity of G3BP1 to participate in SG formation
when cells are subjected to cytotoxic stresses. Therefore we tested
if cisplatin was able to induce SG formation in U2OS cells and if
TAT-RasGAP317–326 could impair this stress-induced response. As
shown in Figure 5A, formation of SGs after treatment with
arsenite was observed, but cisplatin did not induce SG assembly.
Consequently, it is unlikely that the ability of TAT-RasGAP317–326
to sensitize U2OS cells to genotoxin-induced apoptosis relies on an
effect on SGs. Nevertheless, to assess whether TAT-RasGAP317–326,
in conditions where SGs are efficiently induced, modulates their
assembly, U2OS cells were pre-incubated with TAT-RasGAP317–
326 and then incubated with arsenite. Figure 5B–C shows that the
peptide did not affect the number of SG per cell or the number of
cells exhibiting SGs. To directly evaluate whether TAT-Ras-
GAP317–326 affects SG formation induced by G3BP1, U2OS cells
Figure 2. Ectopically-expressed RasGAP and G3BP1 fail to
interact in conditions where RasGAP binds to RhoGAP. Lysates
(1 mg) from HEK293T cells that had been transfected with the indicated
plasmids were immunoprecipitated with an anti-V5 antibody. Immu-
noprecipitated complexes and cell lysates (50 mg) were analyzed by
Western blotting using HA- and V5-specific antibodies. Asterisks: non-
specific bands; #: immunoglobulin heavy chains; white arrowhead:
expected migration of HA-G3BP1.
doi:10.1371/journal.pone.0029024.g002
Figure 3. Endogenous RasGAP binds to RhoGAP but does not
associate with G3BP1. Non-confluent, exponentially growing CCL39
cells (panel A) or U2OS cells (panel B) were lysed in 1% Triton X-100 lysis
buffer and 1 mg of total protein extracts were immunoprecipitated
with an anti-RasGAP antibody. Immunoprecipitated complexes and cell
lysates (50 mg) were analyzed by Western blotting using G3BP1- and
p190 RhoGAP-specific antibodies. T.L.: total lysate; asterisks: non-
specific bands; #: immunoglobulin heavy chains.
doi:10.1371/journal.pone.0029024.g003
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were transfected with a GFP-tagged form of G3BP1 and incubated
or not with the RasGAP-derived peptide. In this case again, the
presence of TAT-RasGAP317–326 did not alter the formation of SGs
(Figure 5D–E). Altogether, these results show, not only that
genotoxins do not induce SG formation, but also that TAT-
RasGAP317–326 does not affect the ability of G3BP1 to mediate the
formation of SGs.
TAT-RasGAP317–326 does not sensitize cancer cells
through the modulation of c-myc mRNA levels
The endoribonuclease activity of G3BP1 was first reported by
its ability to cleave the 39 untranslated region (UTR) of the c-myc
transcript [9,29]. This transcription factor regulates the expres-
sion of hundreds of gene controlling many cellular functions
including cell survival and cell death [30]. It is an oncogene (one
of the first to have been characterized actually) that is deregulated
in many cancer types [31]. It plays a role in apoptosis by
modulating proteins belonging to the Bcl-2 family, such as the
pro-apoptotic BH3 only protein Bim [32,33]. The 39 UTR of the
c-myc mRNA regulates its stability but how it does so is unclear.
There are reports indicating that the 39 UTR favors c-myc mRNA
decay [34,35], while another one provides indirect evidence that
the 39 UTR contributes to c-myc mRNA stabilization [29]. If
TAT-RasGAP317–326 modulates the ability of G3BP1 to cleave
the c-myc mRNA it could affect the sensitivity of cells to apoptosis,
in particular if c-Myc protein levels are increased because this can
lead to cancer cell apoptosis, potentially via induction of Bim
expression [36,37]. We therefore checked if TAT-RasGAP317–326
modulated c-myc mRNA levels and whether it affected c-Myc and
Bim protein expression. Figure 6 shows that TAT-RasGAP317–326
did not modulate c-myc mRNA or c-Myc protein levels. Similarly,
Bim expression was not affected by the peptide (Figure 6B). The
levels of c-Myc and Bim were efficiently decreased by
Actinomycin D, a transcription inhibitor, indicating that the
experimental conditions used in the figure allow detecting down-
modulation of c-Myc and Bim. Finally, G3BP1 protein levels did
not appear to be affected by TAT-RasGAP317–326 but an effect of
the peptide on the transcription or translation of G3BP1 cannot
be ruled out as the half-life of G3BP1 is considerably longer than
c-Myc or Bim (Figure 6B). Collectively these results do not
support the possibility that TAT-RasGAP317–326 modulates the
endoribonuclease activity of G3BP1 to mediate its tumor
sensitization property.
TAT-RasGAP317–326 does not affect G3BP1 subcellular
location
Another possibility we wanted to explore concerned G3BP1
localization. It was reported that in quiescent MEFs, G3BP1
relocalizes to the nucleus and that this relocalization modulates its
phosphorylation status and endoribonuclease activity [29]. Spe-
cifically, when G3BP1 translocates to the nucleus, it becomes
phosphorylated on serine 149 and it functions as an active
endoribonuclease whereas in proliferating cells, possibly in
association with RasGAP, it is dephosphorylated and loses its
ability to cleave RNAs [29]. Therefore we assessed whether TAT-
RasGAP317–326 could alter the sub-cellular location of G3BP1. In
HeLa cells, three-dimensional reconstructions of confocal sections
indicated that G3BP1 was mainly located on a flat section of the
cytoplasm and was absent in areas directly above or below the
nucleus (egg-on-a-plate configuration) (Figure 7A). This permitted
quantitation of the nuclear G3BP1-specific signal to be performed
on conventional epifluorescence images (Figure 7B), which
revealed that 15–20% of G3BP1 was localized in the nucleus
(Figure 7C). This nuclear location was not affected by the
RasGAP-derived peptide however, indicating that the mechanism
by which TAT-RasGAP317–326 sensitizes tumor cells to genotoxin-
induced apoptosis does not rely on modulation of the nuclear
G3BP1 content.
Figure 4. TAT-RasGAP317–326 does not affect the binding of G3BP1 to USP10. HEK293T cells were transfected with the indicated plasmids.
Eight hours later, they were treated with the indicated concentrations of TAT-RasGAP317–326 for an additional 20 hour period at which time they were
lysed. Lysates (1 mg) were subjected to SNTAG pull-down. Pulled-down complexes were analyzed by Western blotting using HA- and SNTAG specific
antibodies. In parallel 50 mg of total cell lysates were subjected to Western blotting analysis using the same antibodies.
doi:10.1371/journal.pone.0029024.g004
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Figure 5. TAT-RasGAP317–326 does not affect G3BP1-induced SG formation. A. U2OS cells were left untreated or incubated with 15 mM
cisplatin, 20 mM TAT-RasGAP317–326, or a combination of the two compounds for 22 hours. Alternatively, the cells were treated with 200 mM arsenite
for 2 hours. The cells were then processed for immunofluorescence analysis using TIA-1- and G3BP1-specific antibodies. Nuclei were stained with
Hoechst 33342. Images were taken with a fluorescent microscope (Nikon Eclipse 90i). Scale bar: 20 mm for the first 4 columns, 5 mm for the last
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G3BP1 ablation does not abolish TAT-RasGAP317–326-
mediated sensitization of cancer cells to cisplatin
The evidence provided so far indicates that G3BP1 is not a
(strong) RasGAP or fragment N2 binding partner and that TAT-
RasGAP317–326 does not modulate any of the known G3BP1
functions. To unequivocally determine whether G3BP1 is needed
for TAT-RasGAP317–326-mediated tumor sensitization, we used
tumor cells in which G3BP1 was silenced and transformed MEFs
from G3BP1 knock-out mice. Silencing G3BP1 using shRNA
directed at the 39 UTR of its mRNA resulted in 90% reduction in
G3BP1 levels in U2OS cells (Figure 8A–B). This however did not
prevent TAT-RasGAP317–326 from sensitizing the cells to cisplatin-
induced death (Figure 8C). Earlier work has demonstrated that
TAT-RasGAP317–326 does not sensitize non-cancer cells to
cisplatin-induced apoptosis [2]. MEFs, which are non-cancer cells,
were indeed not experiencing more cisplatin-induced death in
presence of the peptide (Figure 8F). It is however possible to
transform MEFs with the SV40 large T antigen [38]. We therefore
expressed the large T antigen in MEFs via lentiviral infection
(Figure 8D) and, as expected, this rendered them sensitive to the
genotoxin-sensitizing effect of TAT-RasGAP317–326 (Figure 8F).
However, the peptide displayed identical sensitizing efficacy in
large T-transformed MEFs lacking or not G3BP1 (Figure 8G).
G3BP1 is therefore dispensable for TAT-RasGAP317–326 to
mediate its genotoxin-sensitizing effect on cancer cells.
Discussion
The tumor-sensitizing activity of fragment N2 towards geno-
toxin-induced apoptosis resides in a 10 amino acid stretch
corresponding to amino acids 317–326 of RasGAP [2]. This
peptidic sequence fused to a cell-permeable peptide (the so-called
TAT-RasGAP317–326 peptide) is indeed capable of favoring the
death of several tumor cell lines to various genotoxins [2]. Amino
acids 317–326 of RasGAP correspond exactly to the sequence
reported to mediate the binding of RasGAP to G3BP1 [8]. G3BP1
is a protein regulating mRNA stability, stress granule formation,
and other cellular functions (reviewed in [39]). Formation of stress
granules in cells has been reported to inhibit apoptosis [17].
Additionally, G3BP1 is over-expressed in certain tumors such as
breast cancers [40]. As G3BP1 binds to amino acid 317–326 of
RasGAP, an attractive hypothesis to explain how TAT-Ras-
GAP317–326 sensitizes specifically tumor cells to genotoxin-induced
death was that the peptide inhibits the ability of G3BP1 to form
stress granule and consequently, as stress granules may exert anti-
apoptotic properties [16], decreases the resistance of cancer cells
towards apoptosis. This hypothesis would predict that cells lacking
G3BP1 would not be sensitized by TAT-RasGAP317–326. The
evidence reported in the present study demonstrates that this
hypothesis is incorrect. First, genotoxins did not induce the
formation of stress granules in cancer cells. Formation of stress
granules cannot therefore represent a protective mechanism
against genotoxins in these cells. Secondly, TAT-RasGAP317–326
did not modulate stress granules in conditions known to induce
their formation (e.g. in the presence of arsenite). Third, the peptide
efficiently sensitizes tumor cells lacking G3BP1 to genotoxin-
induced death. It can therefore be unequivocally concluded that
G3BP1 plays no role in the anti-tumor activity of TAT-
RasGAP317–326.
The non-implication of G3BP1 in the function of TAT-
RasGAP317–326 led us to reassess the reported interactions of
G3BP1 with RasGAP. The RasGAP-G3BP1 interaction was first
column. B–C. U2OS cells were pre-incubated or not with 20 mM TAT-RasGAP317–326 for 18 hours and then treated with arsenite (200 mM, 2 hours).
The cells were then processed as in panel A. Scale bar: 20 mm. Quantitation of the number of SGs per cells and the percentage of cells with SGs is
shown in panel C. D–E. U2OS cells were transfected with a plasmid encoding GFP-HA-G3BP1 and 6 hours later were incubated or not with 20 mM
TAT-RasGAP317–326 for an additional 22 hour period. Cells were then fixed and their nuclei stained with Hoechst 33342. Scale bar: 20 mm. Panel E
shows the quantitation of the number of SGs per cells as well as the percentage of cells with SGs.
doi:10.1371/journal.pone.0029024.g005
Figure 6. TAT-RasGAP317–326 does not affect c-mycmRNA and protein levels or expression of the c-Myc target Bim. A. HeLa cells were
treated or not for 24 hours with 20 mM TAT, 20 or 40 mM TAT-RasGAP317–326 (P), or 1 mg/ml actinomycin D (actD). Quantitative RT-PCR was then used
to measure c-myc mRNA levels. B. Alternatively, the cells were lysed and 50 mg of protein extracts were analyzed by Western blotting using the
indicated antibodies. Note that the Bim gene encodes three different forms of the protein, the expected migrations of which are indicated. Asterisks
indicate non-specific bands.
doi:10.1371/journal.pone.0029024.g006
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reported in 1996 [8]. In this report, it was shown by Far Western
blotting that a fusion protein between GST and the SH3 domain
of RasGAP bound to G3BP1 from ER22 cell lysates and that this
binding could be prevented by the addition of a peptide
corresponding to the 317–326 RasGAP amino acid sequence.
We were not able to reproduce these data using U2OS cell
lysates and a recombinant histidine-tagged SH3 domain of
RasGAP as a probe in the Far Western blotting procedure (data
not shown). Moreover, in conditions where RasGAP and G3BP1
bound to known partners (i.e. p190 RhoGAP and USP10,
respectively), no interaction between G3BP1 and RasGAP was
detected (Figures 1, 2, 3). We used exponentially growing cells for
these experiments as it was reported that G3BP1 does not
interact with RasGAP in quiescent cells [9]. The results
presented in Figures 1, 2, and 3 contrast with reports showing
binding of RasGAP to G3BP1 by co-immunoprecipitation
methods [8,9] and by using GST pull-down assays [10]. It has
to be noted however that these studies did not provide controls
excluding a non-specific binding to beads for example. The
interaction between RasGAP and G3BP1 might be occurring in
very specific situations. It has been reported that G3BP1 only
binds to serum-stimulated cells [8,9] and only after specific
cyclical periods of time following the stimulation: association
detected 1 hour, 8 hours and 16 hours after serum addition but
no association seen 10 minutes, 20 minutes, 2 hours, 4 hours
following serum addition [9]. Whether such pattern of G3BP1-
RasGAP association correlates with a known physiological cell
cycle has not been defined.
Figure 7. TAT-RasGAP317–326 does not affect G3BP1 nuclear localization. A. HeLa cells were left untreated or treated for 18 hours with TAT
(20 mM), TAT-RasGAP317–326 (20 or 40 mM). Immunocytochemistry against G3BP1 was then performed (the nuclei were stained in blue with the
Hoechst 33342 dye) and confocal z-stacks were acquired. Three-dimensional images were then built with the Imaris software. Representative
examples of untreated and TAT-RasGAP317–326-treated cells are shown (scale bar: 5 mm). Alternatively, images were taken using conventional
epifluorescence microscopy (scale bar: 10 mm). Panel B depicts representative examples and panel C shows the corresponding quantifications
performed on 80 cells as described in the methods.
doi:10.1371/journal.pone.0029024.g007
G3BP1 and the 317–326 Sequence of RasGAP
PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e29024
We also tried to crosslink RasGAP to G3BP1 in U2OS cell lysates
to visualize a 180 kDa RasGAP-G3BP1 complex, as previously
shown [9], but our analysis failed to reveal such a complex (data not
shown). We were therefore unable to reveal a binding between
G3BP1 and either RasGAP or the SH3 domain-containing
fragment N2 of RasGAP, even when we used techniques, conditions
(e.g. cells incubated with serum) and cell lines (e.g. CCL39) used by
others to report this interaction. A similar lack of interaction
between RasGAP and G3BP1 has been reported earlier by another
laboratory [12]. It is pertinent to mention here that RasGAP was
not found in the proteins identified by mass spectrometry in the
cellular material pulled down with an anti-G3BP1 antibody (Sophie
Martin and Jamal Tazi, unpublished results). The reverse was also
true, i.e. G3BP1 was not identified by mass spectrometry in the
cellular material pulled down with an anti-RasGAP antibody (Hadi
Khalil and Christian Widmann, unpublished results). Last, we took
advantage of the recently crystallized structure of the NTF2 domain
of human G3BP1 (PDB; http://www.pdb.org; #3QN) and the
previously published structure of the RasGAP SH3 domain [41] to
conduct molecular dynamics and docking simulations. This analysis
failed to reveal a preferred binding site between the NTF2 domain
of G3BP1 and the SH3 domain of RasGAP (Figure 9A). As a
control, the ability of USP10 to dock to G3BP1 was also tested.
Figure 9B shows that there was a preferred interaction conforma-
tion between these two proteins at sites demonstrated to interact in
the crystal structure made of these two proteins [42]. In light of all
our results, the possibility that RasGAP is not a genuine G3BP1
partner has to be considered.
Figure 8. G3BP1 silencing does not affect TAT-RasGAP317–326-mediated sensitization of cancer cells to cisplatin-induced apoptosis.
A, B. U2OS were infected with a non-target shRNA control vector or a G3BP1 shRNA-expressing lentivirus. After 72 hours, cells were analyzed by
immunocytochemistry (panel A) and Western blotting (panel B) for the presence of G3BP1. C. Infected cells were incubated with 20 mM cisplatin and
20 mM TAT-RasGAP317–326 for 22 hours as indicated on the figure. Apoptosis was then scored. D. MEFs were infected or not with a large T antigen-
expressing lentivirus and 3 days later the expression of the large T antigen was assessed by immunocytochemistry. E. G3BP1 expression in wild-type
(WT) and G3BP1 knock-out (KO) SV40 large T antigen-transformed MEFs was assessed by Western blotting. F. Alternatively, these cells were
incubated with increasing concentrations of cisplatin in the presence or in the absence of TAT-RasGAP317–326 for 22 hours. Apoptosis was then
measured by scoring the number of cells with pycnotic nuclei. G. Wild-type (WT) and G3BP1 knock-out (KO) SV40 large T-transformed MEFs were
treated as in panel C. Asterisks indicate statistically significant differences; NS: not significant.
doi:10.1371/journal.pone.0029024.g008
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